Solventum Corporation (SOLV)
NYSE: SOLVHealth CareMedical/Dental InstrumentsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 85.88 +0.01%
SOLV stock chart
Technical analysisKey statistics
All statistics- Market cap
- $14.62B
- P/E (TTM)
- 10.51
- Forward P/E
- 11.88
- EPS (TTM)
- $8.17
- Dividend yield
- None
- 52-week range
- 62.38 – 94.16
- Day range
- 85.30 – 87.25
- Volume / Avg
- 981.13K / 1.02M
- Beta
- —
- Shares outstanding
- 170.22M
- Next earnings
- Nov 5, 2026
52-week range
SOLV stock today
Shares of Solventum (SOLV) finished lower on Oct 7 at $85.88, a drop of 1.33% or $1.16 per share, versus the S&P 500's 0.22% decline. At this level, SOLV sits in the middle of its 52-week range of $62.38 to $94.16: 8.8% below the high, set on Sep 1, 2026 and 37.7% above the low. SOLV is up 8.4% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 19.0%.
At 10.5x trailing earnings, Solventum trades below the peer-group median of 29.6x. Its forward P/E of 11.9x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year. Solventum's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Solventum
Company profileSolventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Bryan C. Hanson
- Headquarters
- Eagan, MN
- Employees
- 20,584
- IPO year
- 2024
- Website
- solventum.com
Financial highlights
Full financialsIn fiscal 2025, Solventum generated $8.32 billion in revenue, up 0.9% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $1.56 billion (+224.8% year over year), for a net margin of 18.7% versus a median of 16.4% in the prior 3 years. Gross margin was 53.5% (down from 55.6%) and operating margin 26.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Revenue | $8.32B | $8.25B | $8.20B | $8.13B |
| Growth | +0.86% | +0.70% | +0.82% | — |
| Net income | $1.56B | $479.00M | $1.35B | $1.34B |
| EPS (diluted) | $8.88 | $2.76 | $7.79 | $7.78 |
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$94.31+9.82%
- Strong buy 1
- Buy 7
- Hold 5
- Sell 1
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $1.35
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $0.53 vs —
SOLV news
All SOLV newsSolventum peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PENPenumbra Inc. | 316.35 | -0.22% | $12.46B | vs SOLV |
| BAXBaxter International Inc. | 23.97 | -1.60% | $12.39B | vs SOLV |
| GKOSGlaukos Corporation | 172.18 | +6.55% | $10.16B | vs SOLV |
| GMEDGlobus Medical Inc. Class A | 73.75 | -3.51% | $9.90B | vs SOLV |
| PODDInsulet Corporation | 134.36 | -0.27% | $9.32B | vs SOLV |
| MMEDMiniMed Group Inc. | 19.11 | -2.70% | $5.38B | vs SOLV |
| STVNStevanato Group S.p.A. | 19.44 | -2.11% | $5.31B | vs SOLV |
| TFXTeleflex Incorporated | 124.48 | -0.21% | $5.27B | vs SOLV |
Indexes, lists and sector
Index membership
Solventum stock FAQ
What is Solventum's stock price today?
SOLV last traded at $85.88 as of Oct 7, 4:00 PM EDT, down 1.33% on the day. Prices are delayed at least 15 minutes.
When is Solventum's next earnings date?
Solventum is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $1.35.
What is SOLV's P/E ratio?
SOLV trades at a trailing P/E ratio of 10.51 and a forward P/E of 11.88, compared with a median of 29.6 for its closest peers.
Is Solventum in the S&P 500?
Yes. Solventum (SOLV) is a constituent of the S&P 500 index.
Who is Solventum's CEO?
Mr. Bryan C. Hanson is the chief executive officer of Solventum Corporation, which has about 20,584 employees.
What is the SOLV 52-week high?
The 52-week high for SOLV is $94.16 and the 52-week low is $62.38. The stock is currently 8.8% below its high.